SecBot SecBot

NRXS

Neuraxis, INC
NYSE· Electromedical & Electrotherapeutic Apparatus· Inc. DE· CIK 0001933567 Healthcare & Medical Devices
$7.25 −0.15 (−2.03%)
Oct 26 4:00 PM ET · prev $7.40
Market cap
$95.4M
Micro cap
Median target
$11.00
+52% · range $9.00–13.00
Next earnings
Nov 17
in 21 days · EPS est. −$0.21
1 year
+133.1%
from $3.11 · Oct 27
30 days
−2.0%
from $7.40
52-week range
$2.31–8.81
−18% from high · low Nov 17
Avg volume 20D
146.3K
Oct 15 spike 1.13M
Short interest
🔒 Subscribers only
Insider net
+$44.2K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH Neuraxis's S-3 shelf registration (File No. 333-297651) became effective on August 3, 2026, allowing the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $44.2K. No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 2 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.115 → −$0.210 over 90 days.

  • TrendUPTREND

    7% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD335,793$2.5M
RENAISSANCE TECHNOLOGIES LLCDOUBLED169,400$1.2M
MARSHALL WACE, LLPADD128,755$941.2K
BlackRock, Inc.DOUBLED58,652$428.7K
Centiva Capital, LPTRIM37,526$274.3K
NORTHERN TRUST CORPADD23,083$168.7K
Vestmark Advisory Solutions, Inc.ADD14,300$104.5K
HRT FINANCIAL LPADD14,322$104.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +52%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Mar 20, 2026Craig-Hallum
MAINTAIN
MAINTAINBuy
Dec 22, 2025Craig-Hallum
MAINTAIN
MAINTAINBuy
Jun 16, 2025Craig-Hallum
INITIATE
INITIATEBuy

Insider ledger

Form 4
$44.2K
bought · 3 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 8, 2026
Carrico Thomas Joeseph
CRO, CCO, CPO
BUY$1.6K
Oct 8, 2026
Henrichs Timothy Robert
Chief Financial Officer
BUY$9.4K
Oct 8, 2026
Carrico Brian Allen
Chief Executive Officer
BUY$1.3K
Aug 24, 2026
Miranda Adrian
CMO, SVP Science & Tech
AWARD337,204 sh
Aug 24, 2026
Carrico Thomas Joeseph
CRO, CCO, CPO
AWARD306,236 sh
Aug 24, 2026
Carrico Thomas Joeseph
CRO, CCO, CPO
AWARD193,678 sh
Aug 24, 2026
Miranda Adrian
CMO, SVP Science & Tech
AWARD199,106 sh
Aug 24, 2026
Carrico Brian Allen
Chief Executive Officer
AWARD199,188 sh

Earnings setup

Estimates
Nov 17
reports in 21 days
−$0.21
EPS estimate, this quarter
−83%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.21–-$0.21+0.0%$2.1M
Next Q-$0.18-$0.18–-$0.18+0.0%$2.6M
Current FY-$0.76-$0.76–-$0.76+0.0%$8.3M
Next FY-$0.27-$0.27–-$0.27+0.0%$19.8M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
Total national coverage footprint for PENFS increases to over 147 million covered lives...
Oct 14, 2026 SEC
Neuraxis declared a Q3 2026 stock dividend on its Series B Preferred Stock, payable in common shares. Approximately…
8-K — Impact 2/10
Oct 8, 2026 Insider
Carrico Thomas Joeseph bought 328 shares
CRO, CCO, CPO @ $4.84 ($1.6K)
Oct 8, 2026 Insider
Henrichs Timothy Robert bought 1,937 shares
Chief Financial Officer @ $4.84 ($9.4K)
Oct 8, 2026 Insider
Carrico Brian Allen bought 268 shares
Chief Executive Officer @ $4.84 ($1.3K)
Aug 19, 2026 SEC
Neuraxis filed an 8-K detailing the effectiveness of a stock option exchange on July 24, 2026, where 1,319,394…
8-K — Impact 2/10
Aug 11, 2026 SEC
NeurAxis reported Q2 2026 revenue of $1.9M (+116% YoY) and EPS of -$0.19 (40.6% beat vs -$0.32 consensus), driven by…
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
335,793 shares ($2.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
NRXS Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Oct 15, 2026
Press release
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
Total national coverage footprint for PENFS increases to over 147 million covered lives...
Sep 16, 2026
Press release
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
Total national coverage footprint for PENFS increases to over 120 million covered lives Total national coverage footprint for PENFS increases to…
Aug 11, 2026
Earnings
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, August 11 at 9:00 am ET Conference call will be held today, Tuesday, August 11 at 9:00 am ET
Aug 11, 2026
Earnings date
NRXS Q2 2026 Earnings Scheduled — 2026-08-11
May 12, 2026
Earnings
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, May 12 at 9:00 am ET Conference call will be held today, Tuesday, May 12 at 9:00 am ET

SecBot reports

12 filings · 2 press releases · 2 bullish · 2 bearish · 2 mixed · 6 neutral
All NRXS filing & press-release reports (14)